Logo image of CELU

CELULARITY INC-A (CELU) Stock Fundamental Analysis

NASDAQ:CELU - Nasdaq - US1511902041 - Common Stock - Currency: USD

1.75  -0.01 (-0.57%)

Fundamental Rating

2

Overall CELU gets a fundamental rating of 2 out of 10. We evaluated CELU against 559 industry peers in the Biotechnology industry. CELU may be in some trouble as it scores bad on both profitability and health. CELU is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year CELU has reported negative net income.
CELU had a negative operating cash flow in the past year.
In the past 5 years CELU reported 4 times negative net income.
In the past 5 years CELU always reported negative operating cash flow.
CELU Yearly Net Income VS EBIT VS OCF VS FCFCELU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

CELU's Return On Assets of -43.62% is in line compared to the rest of the industry. CELU outperforms 54.56% of its industry peers.
CELU has a worse Return On Equity (-654.96%) than 80.68% of its industry peers.
Industry RankSector Rank
ROA -43.62%
ROE -654.96%
ROIC N/A
ROA(3y)-58.77%
ROA(5y)-40.28%
ROE(3y)-375.51%
ROE(5y)-245.63%
ROIC(3y)N/A
ROIC(5y)N/A
CELU Yearly ROA, ROE, ROICCELU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

CELU has a Gross Margin of 72.36%. This is amongst the best in the industry. CELU outperforms 82.83% of its industry peers.
CELU's Gross Margin has improved in the last couple of years.
CELU does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 72.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.74%
GM growth 5YN/A
CELU Yearly Profit, Operating, Gross MarginsCELU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

0

2. Health

2.1 Basic Checks

CELU does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CELU has more shares outstanding
CELU has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CELU has a worse debt to assets ratio.
CELU Yearly Shares OutstandingCELU Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
CELU Yearly Total Debt VS Total AssetsCELU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -10.13, we must say that CELU is in the distress zone and has some risk of bankruptcy.
CELU has a Altman-Z score of -10.13. This is in the lower half of the industry: CELU underperforms 73.88% of its industry peers.
A Debt/Equity ratio of 4.79 is on the high side and indicates that CELU has dependencies on debt financing.
CELU has a worse Debt to Equity ratio (4.79) than 83.36% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.79
Debt/FCF N/A
Altman-Z -10.13
ROIC/WACCN/A
WACC8.28%
CELU Yearly LT Debt VS Equity VS FCFCELU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

CELU has a Current Ratio of 0.38. This is a bad value and indicates that CELU is not financially healthy enough and could expect problems in meeting its short term obligations.
CELU has a worse Current ratio (0.38) than 93.56% of its industry peers.
A Quick Ratio of 0.28 indicates that CELU may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.28, CELU is doing worse than 94.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.38
Quick Ratio 0.28
CELU Yearly Current Assets VS Current LiabilitesCELU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 76.46% over the past year.
Looking at the last year, CELU shows a very strong growth in Revenue. The Revenue has grown by 138.11%.
The Revenue has been growing by 36.47% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)76.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-210.43%
Revenue 1Y (TTM)138.11%
Revenue growth 3Y36.47%
Revenue growth 5YN/A
Sales Q2Q%49.7%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
Based on estimates for the next years, CELU will show a very strong growth in Revenue. The Revenue will grow by 98.27% on average per year.
EPS Next Y26.32%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year233.89%
Revenue Next 2Y89.48%
Revenue Next 3Y144.15%
Revenue Next 5Y98.27%

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CELU Yearly Revenue VS EstimatesCELU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
CELU Yearly EPS VS EstimatesCELU Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CELU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CELU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CELU Price Earnings VS Forward Price EarningsCELU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CELU Per share dataCELU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CELU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELULARITY INC-A

NASDAQ:CELU (6/13/2025, 8:00:00 PM)

1.75

-0.01 (-0.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2025-05-09/amc
Earnings (Next)10-14 2025-10-14
Inst Owners14.64%
Inst Owner Change8.09%
Ins Owners14.45%
Ins Owner Change0.3%
Market Cap41.91M
Analysts82.86
Price TargetN/A
Short Float %14.06%
Short Ratio21.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.77
P/FCF N/A
P/OCF N/A
P/B 4.74
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.66
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS2.26
BVpS0.37
TBVpS-0.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.62%
ROE -654.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 72.36%
FCFM N/A
ROA(3y)-58.77%
ROA(5y)-40.28%
ROE(3y)-375.51%
ROE(5y)-245.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.74%
GM growth 5YN/A
F-Score5
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 4.79
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.97%
Cap/Sales 3.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.38
Quick Ratio 0.28
Altman-Z -10.13
F-Score5
WACC8.28%
ROIC/WACCN/A
Cap/Depr(3y)39.96%
Cap/Depr(5y)N/A
Cap/Sales(3y)16.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-210.43%
EPS Next Y26.32%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)138.11%
Revenue growth 3Y36.47%
Revenue growth 5YN/A
Sales Q2Q%49.7%
Revenue Next Year233.89%
Revenue Next 2Y89.48%
Revenue Next 3Y144.15%
Revenue Next 5Y98.27%
EBIT growth 1Y-1173.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y81.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y83.45%
OCF growth 3YN/A
OCF growth 5YN/A